Verastem (VSTM) Net Cash Flow Growth (3y) (2014 - 2026)
Verastem (VSTM) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 32.17% |
| 10 | Verastem | 619.24 Mn | 421.41 Mn | 15.90 Mn | -54.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.91% |
| Dec 31, 2025 | 174.74% |
| Sep 30, 2025 | -47.47% |
| Jun 30, 2025 | 39.39% |
| Mar 31, 2025 | 4.17% |
| Dec 31, 2024 | -99.62% |
| Sep 30, 2024 | 261.64% |
| Jun 30, 2024 | 27.99% |
| Mar 31, 2024 | 28.24% |
| Dec 31, 2023 | 49.54% |
| Sep 30, 2023 | -58.09% |
| Jun 30, 2023 | 120.00% |
| Mar 31, 2023 | -36.92% |
| Dec 31, 2022 | 47.49% |
| Sep 30, 2022 | 52.64% |
| Jun 30, 2022 | -7.13% |
| Mar 31, 2022 | 38.62% |
| Dec 31, 2021 | -80.35% |
| Sep 30, 2021 | 74.12% |
| Jun 30, 2021 | -28.08% |